AcuFocus, which makes the Kamra eye inlay for treating nearsightedness, said it raised nearly $1.9 million in a round of debt funding.
Irvine, Calif.-based AcuFocus said in a regulatory filing that the round included 14 unnamed investors. The company hopes to raise a total of $2.5 million, according to the filing. The company pulled in nearly $4.1 million an another debt round in March.
AcuFocus is backed by HealthCare Royalty Partners, SV Life Sciences, Versant Ventures, Carlyle Group, Accuitive Medical Ventures and Medtronic (NYSE:MDT). The company raised $21 million in September 2014, just before landing CE Mark approval in the European Union for its Kamra device, which is designed to be inserted into the cornea to treat presbyopia.
Kamra won FDA approval in April 2015 after a narrow win at an advisory panel hearing and has been implanted more than 1,000 times, according to AcuFocus.
